Medtronic/Kyphon merger gets early US OK:
This article was originally published in Clinica
Executive Summary
Medtronic's proposed $3.9bn acquisition of balloon kyphoplasty specialist Kyphon has received the go-ahead from US regulators, who agreed to an early termination of the waiting period required under the US antitrust act. The transaction still requires regulatory approval from several other jurisdictions, as well as approval from Kyphon's shareholders, who will vote in a special meeting set for October 16.